Tang Capital Management Exits Kezar Life Sciences Following Aurinia Acquisition
summarizeSummary
Tang Capital Management and related entities have filed an amended Schedule 13D, confirming they no longer hold shares in Kezar Life Sciences following its acquisition by Aurinia Pharmaceuticals on May 11, 2026.
check_boxKey Events
-
Merger Completion Confirmed
Kezar Life Sciences was acquired by Aurinia Pharma U.S., Inc. on May 11, 2026, resulting in the cancellation of all outstanding shares.
-
Major Shareholder Exit
Tang Capital Management and its affiliates, who previously held a 9.0% stake, no longer own any shares in Kezar Life Sciences as of the merger completion date.
-
Final Ownership Disclosure
This Schedule 13D/A serves as the final amendment from Tang Capital, formally disclosing their exit from beneficial ownership of Kezar.
auto_awesomeAnalysis
This filing provides formal notification that Tang Capital Management, previously a significant shareholder with a 9.0% stake, has ceased to be a beneficial owner of Kezar Life Sciences. This change in ownership is a direct result of Aurinia Pharmaceuticals' acquisition of Kezar, which completed on May 11, 2026, leading to the cancellation of all outstanding Kezar shares. It marks the final disposition of their investment in the now-private company.
At the time of this filing, KZR was trading at $7.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.9M. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.